<!DOCTYPE html><!--Xd76CUF9_ROIgMmQRWBvv--><html lang="en" data-scroll-behavior="smooth"><head><meta charSet="utf-8"/><meta name="viewport" content="width=device-width, initial-scale=1"/><link rel="preload" href="/_next/static/media/e4af272ccee01ff0-s.p.woff2" as="font" crossorigin="" type="font/woff2"/><link rel="stylesheet" href="/_next/static/css/5884bd3aaf456fca.css" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/931b179cff3131dc.css" data-precedence="next"/><link rel="preload" as="script" fetchPriority="low" href="/_next/static/chunks/webpack-86b9a0a63f5f9169.js"/><script src="/_next/static/chunks/4bd1b696-cf72ae8a39fa05aa.js" async=""></script><script src="/_next/static/chunks/964-69097a61540f27b4.js" async=""></script><script src="/_next/static/chunks/main-app-51e1b6f5714d9477.js" async=""></script><script src="/_next/static/chunks/874-437a265a67d6cfee.js" async=""></script><script src="/_next/static/chunks/455-28b7fbb360ee31f4.js" async=""></script><script src="/_next/static/chunks/187-9968f21ecf164052.js" async=""></script><script src="/_next/static/chunks/app/layout-fa7cba4b34f22bd9.js" async=""></script><script src="/_next/static/chunks/496-4ec65330a7ffa1d1.js" async=""></script><script src="/_next/static/chunks/app/drugs/%5Bslug%5D/page-92c303eaeef28156.js" async=""></script><link rel="dns-prefetch" href="//fonts.googleapis.com"/><link rel="preconnect" href="https://fonts.googleapis.com" crossorigin="anonymous"/><link rel="preload" href="/og-image.png" as="image"/><link rel="icon" type="image/x-icon" href="/favicon.ico"/><link rel="icon" type="image/png" sizes="32x32" href="/og-image.png"/><link rel="icon" type="image/png" sizes="16x16" href="/og-image.png"/><link rel="apple-touch-icon" href="/og-image.png"/><meta name="theme-color" content="#3B82F6"/><link rel="manifest" href="/manifest.json"/><meta name="next-size-adjust" content=""/><title>Mounjaro (tirzepatide) | drugfacts.wiki</title><meta name="description" content="Complete prescribing information for Mounjaro (tirzepatide). Diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Dosing, s..."/><meta name="author" content="drugfacts.wiki"/><meta name="keywords" content="mounjaro, tirzepatide, glp-1/gip receptor agonist, prescribing information, drug facts, medical information, diabetes"/><meta name="robots" content="index, follow"/><meta name="googlebot" content="index, follow, max-video-preview:-1, max-image-preview:large, max-snippet:-1"/><meta property="og:title" content="Mounjaro - Professional Drug Information"/><meta property="og:description" content="Diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Complete prescribing information including dosing, contraindications, and safety data."/><meta property="og:site_name" content="drugfacts.wiki"/><meta property="og:type" content="article"/><meta name="twitter:card" content="summary_large_image"/><meta name="twitter:title" content="Mounjaro - Professional Drug Information"/><meta name="twitter:description" content="Diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Complete prescribing information including dosing, contraindications, and safety data."/><script src="/_next/static/chunks/polyfills-42372ed130431b0a.js" noModule=""></script></head><body class="__className_e8ce0c"><div hidden=""><!--$--><!--/$--></div><div class="flex min-h-screen flex-col"><header class="bg-white shadow-sm border-b border-medical-gray-200 sticky top-0 z-50"><div class="max-w-7xl mx-auto px-4 sm:px-6 lg:px-8"><div class="flex justify-between items-center h-16"><div class="flex items-center space-x-4 transition-all duration-300 ease-in-out opacity-100"><div class="flex-shrink-0"><a class="block" href="/"><h1 class="text-xl font-bold text-medical-blue cursor-pointer">drugfacts.wiki</h1></a></div><nav class="hidden md:flex space-x-6"><a class="text-medical-gray-600 hover:text-medical-blue transition-colors" href="/">Home</a><a class="text-medical-gray-600 hover:text-medical-blue transition-colors" href="/search/">Search Drugs</a><a class="text-medical-gray-600 hover:text-medical-blue transition-colors" href="/therapeutic-classes/">Therapeutic Classes</a><a class="text-medical-gray-600 hover:text-medical-blue transition-colors" href="/manufacturers/">Manufacturers</a></nav></div><div class="transition-all duration-300 ease-in-out mx-8 flex-1 max-w-lg"><form class="relative" role="search"><label for="search-input" class="sr-only">Search for drug information</label><input type="text" class="flex h-10 bg-background px-3 text-base ring-offset-background file:border-0 file:bg-transparent file:text-sm file:font-medium file:text-foreground placeholder:text-muted-foreground focus-visible:outline-none focus-visible:ring-2 focus-visible:ring-ring focus-visible:ring-offset-2 disabled:cursor-not-allowed disabled:opacity-50 md:text-sm transition-all duration-300 ease-in-out pl-10 pr-4 py-2 border border-medical-gray-300 rounded-lg focus:ring-2 focus:ring-medical-blue focus:border-transparent w-full" id="search-input" placeholder="Search drug names, generics, or indications..." aria-label="Search for drug information" value=""/><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-search absolute left-3 top-1/2 transform -translate-y-1/2 text-medical-gray-400 h-4 w-4" aria-hidden="true"><circle cx="11" cy="11" r="8"></circle><path d="m21 21-4.3-4.3"></path></svg><button type="submit" class="sr-only">Search</button></form></div><div class="flex items-center space-x-4"><button class="inline-flex items-center justify-center gap-2 whitespace-nowrap text-sm font-medium ring-offset-background transition-colors focus-visible:outline-none focus-visible:ring-2 focus-visible:ring-ring focus-visible:ring-offset-2 disabled:pointer-events-none disabled:opacity-50 [&amp;_svg]:pointer-events-none [&amp;_svg]:size-4 [&amp;_svg]:shrink-0 hover:bg-accent hover:text-accent-foreground h-9 rounded-md px-3 md:hidden" aria-label="Open navigation menu" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ddb_" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-menu h-4 w-4"><line x1="4" x2="20" y1="12" y2="12"></line><line x1="4" x2="20" y1="6" y2="6"></line><line x1="4" x2="20" y1="18" y2="18"></line></svg></button></div></div></div></header><main class="flex-1" role="main"><div class="container mx-auto px-2 sm:px-4 py-4 sm:py-8"><div class="grid grid-cols-1 lg:grid-cols-4 gap-4 lg:gap-8"><div class="lg:col-span-3"><div class="rounded-lg border bg-card text-card-foreground shadow-sm mb-4 sm:mb-8"><div class="p-4 sm:p-6 lg:p-8"><div class="flex flex-col lg:flex-row lg:items-start lg:justify-between"><div class="flex-1"><div class="flex flex-col sm:flex-row sm:items-center sm:space-x-3 mb-2 space-y-2 sm:space-y-0"><h1 class="text-2xl sm:text-3xl font-bold text-medical-gray-800 break-words">Mounjaro<sup>®</sup></h1><div class="inline-flex items-center rounded-full border px-2.5 py-0.5 text-xs font-semibold transition-colors focus:outline-none focus:ring-2 focus:ring-ring focus:ring-offset-2 border-transparent hover:bg-primary/80 bg-medical-blue text-white self-start">Prescription Only</div></div><h2 class="text-xl text-medical-gray-600 mb-4">(tirzepatide)</h2><div class="grid grid-cols-1 sm:grid-cols-2 lg:grid-cols-4 gap-4 mb-6"><div><p class="text-sm font-medium text-medical-gray-500">Manufacturer</p><p class="text-medical-gray-800">Eli Lilly and Company</p></div><div><p class="text-sm font-medium text-medical-gray-500">Generic Name</p><p class="text-medical-gray-800">tirzepatide</p></div><div><p class="text-sm font-medium text-medical-gray-500">Therapeutic Class</p><p class="text-medical-gray-800">GLP-1/GIP Receptor Agonist</p></div><div><p class="text-sm font-medium text-medical-gray-500">Effective Date</p><p class="text-medical-gray-800">7/20/2025</p></div></div><div class="grid grid-cols-1 sm:grid-cols-2 gap-4 mb-6 bg-medical-gray-50 p-3 sm:p-4 rounded-lg"><div><p class="text-sm font-medium text-medical-gray-500">FDA Set ID</p><p class="text-xs text-medical-gray-600 font-mono">d2d7da5d-ad07-4228-955f-cf7e355c8cc0</p></div><div><p class="text-sm font-medium text-medical-gray-500">Full Title</p><p class="text-medical-gray-800">Mounjaro<!-- --> - <!-- -->Eli Lilly and Company</p></div></div><div class="bg-medical-gray-50 rounded-lg p-4"><h3 class="font-semibold text-medical-gray-800 mb-2">Key Prescribing Highlights</h3><ul class="text-sm text-medical-gray-700 space-y-1"><li>• <!-- -->Starting dose: 2.5 mg subcutaneous once weekly</li><li>• <!-- -->Dual GIP/GLP-1 receptor agonist</li><li>• <!-- -->Indicated for Type 2 diabetes mellitus</li><li>• <!-- -->Contains boxed warning</li></ul></div></div><div class="mt-6 lg:mt-0 lg:ml-8 flex-shrink-0"><button class="inline-flex items-center justify-center gap-2 whitespace-nowrap rounded-md text-sm font-medium ring-offset-background transition-colors focus-visible:outline-none focus-visible:ring-2 focus-visible:ring-ring focus-visible:ring-offset-2 disabled:pointer-events-none disabled:opacity-50 [&amp;_svg]:pointer-events-none [&amp;_svg]:size-4 [&amp;_svg]:shrink-0 border border-input bg-background hover:bg-accent hover:text-accent-foreground h-10 px-4 py-2"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-share mr-2 h-4 w-4"><path d="M4 12v8a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2v-8"></path><polyline points="16 6 12 2 8 6"></polyline><line x1="12" x2="12" y1="2" y2="15"></line></svg>Share</button></div></div></div></div><div dir="ltr" data-orientation="horizontal" class="mt-4 sm:mt-6"><div role="tablist" aria-orientation="horizontal" class="items-center justify-center text-muted-foreground flex w-full h-auto p-1 bg-gray-100 border border-gray-200 rounded-lg" tabindex="-1" data-orientation="horizontal" style="outline:none"><button type="button" role="tab" aria-selected="true" aria-controls="radix-_R_4lfiv5udb_-content-professional" data-state="active" id="radix-_R_4lfiv5udb_-trigger-professional" class="inline-flex items-center justify-center whitespace-nowrap ring-offset-background focus-visible:outline-none focus-visible:ring-2 focus-visible:ring-ring focus-visible:ring-offset-2 disabled:pointer-events-none disabled:opacity-50 data-[state=active]:bg-background data-[state=active]:text-foreground text-xs sm:text-sm px-4 sm:px-6 py-3 text-center font-medium transition-all duration-200 data-[state=active]:!bg-blue-600 data-[state=active]:!text-white data-[state=active]:!border-blue-600 data-[state=active]:shadow-md data-[state=inactive]:bg-transparent data-[state=inactive]:text-gray-600 data-[state=inactive]:hover:text-blue-600 data-[state=inactive]:hover:bg-blue-50 rounded-lg border border-transparent flex-1 relative" tabindex="-1" data-orientation="horizontal" data-radix-collection-item=""><span class="block sm:hidden">Professional</span><span class="hidden sm:block">Professional Info</span></button><button type="button" role="tab" aria-selected="false" aria-controls="radix-_R_4lfiv5udb_-content-patient" data-state="inactive" id="radix-_R_4lfiv5udb_-trigger-patient" class="inline-flex items-center justify-center whitespace-nowrap ring-offset-background focus-visible:outline-none focus-visible:ring-2 focus-visible:ring-ring focus-visible:ring-offset-2 disabled:pointer-events-none disabled:opacity-50 data-[state=active]:bg-background data-[state=active]:text-foreground text-xs sm:text-sm px-4 sm:px-6 py-3 text-center font-medium transition-all duration-200 data-[state=active]:!bg-blue-600 data-[state=active]:!text-white data-[state=active]:!border-blue-600 data-[state=active]:shadow-md data-[state=inactive]:bg-transparent data-[state=inactive]:text-gray-600 data-[state=inactive]:hover:text-blue-600 data-[state=inactive]:hover:bg-blue-50 rounded-lg border border-transparent flex-1 relative" tabindex="-1" data-orientation="horizontal" data-radix-collection-item=""><span class="block sm:hidden">Patient</span><span class="hidden sm:block">Patient-Friendly</span></button><button type="button" role="tab" aria-selected="false" aria-controls="radix-_R_4lfiv5udb_-content-faq" data-state="inactive" id="radix-_R_4lfiv5udb_-trigger-faq" class="inline-flex items-center justify-center whitespace-nowrap ring-offset-background focus-visible:outline-none focus-visible:ring-2 focus-visible:ring-ring focus-visible:ring-offset-2 disabled:pointer-events-none disabled:opacity-50 data-[state=active]:bg-background data-[state=active]:text-foreground text-xs sm:text-sm px-4 sm:px-6 py-3 text-center font-medium transition-all duration-200 data-[state=active]:!bg-blue-600 data-[state=active]:!text-white data-[state=active]:!border-blue-600 data-[state=active]:shadow-md data-[state=inactive]:bg-transparent data-[state=inactive]:text-gray-600 data-[state=inactive]:hover:text-blue-600 data-[state=inactive]:hover:bg-blue-50 rounded-lg border border-transparent flex-1 relative" tabindex="-1" data-orientation="horizontal" data-radix-collection-item=""><span class="block sm:hidden">FAQ</span><span class="hidden sm:block">FAQ &amp; Related</span></button></div><div data-state="active" data-orientation="horizontal" role="tabpanel" aria-labelledby="radix-_R_4lfiv5udb_-trigger-professional" id="radix-_R_4lfiv5udb_-content-professional" tabindex="0" class="ring-offset-background focus-visible:outline-none focus-visible:ring-2 focus-visible:ring-ring focus-visible:ring-offset-2 space-y-4 sm:space-y-6 mt-4 sm:mt-6" style="animation-duration:0s"><div class="bg-blue-50 border border-blue-200 rounded-lg p-1"><div class="rounded-lg border bg-card text-card-foreground shadow-sm mb-8" id="highlights"><button class="gap-2 whitespace-nowrap text-sm font-medium ring-offset-background transition-colors focus-visible:outline-none focus-visible:ring-2 focus-visible:ring-ring focus-visible:ring-offset-2 disabled:pointer-events-none disabled:opacity-50 [&amp;_svg]:pointer-events-none [&amp;_svg]:size-4 [&amp;_svg]:shrink-0 hover:text-accent-foreground h-10 w-full flex items-start justify-between p-4 sm:p-6 text-left hover:bg-gray-50 rounded-none min-h-[60px]"><h2 class="text-base sm:text-lg md:text-xl font-semibold text-medical-gray-800 pr-4 leading-tight card-title-responsive">HIGHLIGHTS</h2><div class="flex-shrink-0 mt-1"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-chevron-up text-medical-gray-400 h-4 w-4 sm:h-5 sm:w-5"><path d="m18 15-6-6-6 6"></path></svg></div></button><div class="p-6 px-4 sm:px-6 pb-4 sm:pb-6 pt-0"><div class="prose max-w-none"><h4 class="text-sm font-medium text-blue-900 mb-2">Dosage and Administration Highlights</h4><div><p>The recommended starting dosage of MOUNJARO is 2.5 mg injected subcutaneously once weekly. After 4 weeks, increase the dosage to 5 mg injected subcutaneously once weekly.</p></div></div></div></div></div><div class="border-2 border-red-500 bg-red-50 rounded-lg p-1"><div class="rounded-lg border bg-card text-card-foreground shadow-sm mb-8" id="boxed-warning"><button class="gap-2 whitespace-nowrap text-sm font-medium ring-offset-background transition-colors focus-visible:outline-none focus-visible:ring-2 focus-visible:ring-ring focus-visible:ring-offset-2 disabled:pointer-events-none disabled:opacity-50 [&amp;_svg]:pointer-events-none [&amp;_svg]:size-4 [&amp;_svg]:shrink-0 hover:text-accent-foreground h-10 w-full flex items-start justify-between p-4 sm:p-6 text-left hover:bg-gray-50 rounded-none min-h-[60px]"><h2 class="text-base sm:text-lg md:text-xl font-semibold text-medical-gray-800 pr-4 leading-tight card-title-responsive">BOXED WARNING</h2><div class="flex-shrink-0 mt-1"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-chevron-up text-medical-gray-400 h-4 w-4 sm:h-5 sm:w-5"><path d="m18 15-6-6-6 6"></path></svg></div></button><div class="p-6 px-4 sm:px-6 pb-4 sm:pb-6 pt-0"><div class="prose max-w-none"><p><strong>WARNING: RISK OF THYROID C-CELL TUMORS</strong></p><p>In rodents, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors. It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans.</p></div></div></div></div><div class="rounded-lg border bg-card text-card-foreground shadow-sm mb-8" id="indications"><button class="gap-2 whitespace-nowrap text-sm font-medium ring-offset-background transition-colors focus-visible:outline-none focus-visible:ring-2 focus-visible:ring-ring focus-visible:ring-offset-2 disabled:pointer-events-none disabled:opacity-50 [&amp;_svg]:pointer-events-none [&amp;_svg]:size-4 [&amp;_svg]:shrink-0 hover:text-accent-foreground h-10 w-full flex items-start justify-between p-4 sm:p-6 text-left hover:bg-gray-50 rounded-none min-h-[60px]"><h2 class="text-base sm:text-lg md:text-xl font-semibold text-medical-gray-800 pr-4 leading-tight card-title-responsive">INDICATIONS AND USAGE</h2><div class="flex-shrink-0 mt-1"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-chevron-up text-medical-gray-400 h-4 w-4 sm:h-5 sm:w-5"><path d="m18 15-6-6-6 6"></path></svg></div></button><div class="p-6 px-4 sm:px-6 pb-4 sm:pb-6 pt-0"><div class="prose max-w-none"><p>MOUNJARO is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.</p></div></div></div><div class="rounded-lg border bg-card text-card-foreground shadow-sm mb-8" id="dosage"><button class="gap-2 whitespace-nowrap text-sm font-medium ring-offset-background transition-colors focus-visible:outline-none focus-visible:ring-2 focus-visible:ring-ring focus-visible:ring-offset-2 disabled:pointer-events-none disabled:opacity-50 [&amp;_svg]:pointer-events-none [&amp;_svg]:size-4 [&amp;_svg]:shrink-0 hover:text-accent-foreground h-10 w-full flex items-start justify-between p-4 sm:p-6 text-left hover:bg-gray-50 rounded-none min-h-[60px]"><h2 class="text-base sm:text-lg md:text-xl font-semibold text-medical-gray-800 pr-4 leading-tight card-title-responsive">DOSAGE AND ADMINISTRATION</h2><div class="flex-shrink-0 mt-1"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-chevron-up text-medical-gray-400 h-4 w-4 sm:h-5 sm:w-5"><path d="m18 15-6-6-6 6"></path></svg></div></button><div class="p-6 px-4 sm:px-6 pb-4 sm:pb-6 pt-0"><div class="prose max-w-none"><p>The recommended starting dosage of MOUNJARO is 2.5 mg injected subcutaneously once weekly. After 4 weeks, increase the dosage to 5 mg injected subcutaneously once weekly.</p></div></div></div><div class="rounded-lg border bg-card text-card-foreground shadow-sm mb-8" id="contraindications"><button class="gap-2 whitespace-nowrap text-sm font-medium ring-offset-background transition-colors focus-visible:outline-none focus-visible:ring-2 focus-visible:ring-ring focus-visible:ring-offset-2 disabled:pointer-events-none disabled:opacity-50 [&amp;_svg]:pointer-events-none [&amp;_svg]:size-4 [&amp;_svg]:shrink-0 hover:text-accent-foreground h-10 w-full flex items-start justify-between p-4 sm:p-6 text-left hover:bg-gray-50 rounded-none min-h-[60px]"><h2 class="text-base sm:text-lg md:text-xl font-semibold text-medical-gray-800 pr-4 leading-tight card-title-responsive">CONTRAINDICATIONS</h2><div class="flex-shrink-0 mt-1"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-chevron-up text-medical-gray-400 h-4 w-4 sm:h-5 sm:w-5"><path d="m18 15-6-6-6 6"></path></svg></div></button><div class="p-6 px-4 sm:px-6 pb-4 sm:pb-6 pt-0"><div class="prose max-w-none"><p>MOUNJARO is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2.</p></div></div></div><div class="rounded-lg border bg-card text-card-foreground shadow-sm mb-8" id="warnings"><button class="gap-2 whitespace-nowrap text-sm font-medium ring-offset-background transition-colors focus-visible:outline-none focus-visible:ring-2 focus-visible:ring-ring focus-visible:ring-offset-2 disabled:pointer-events-none disabled:opacity-50 [&amp;_svg]:pointer-events-none [&amp;_svg]:size-4 [&amp;_svg]:shrink-0 hover:text-accent-foreground h-10 w-full flex items-start justify-between p-4 sm:p-6 text-left hover:bg-gray-50 rounded-none min-h-[60px]"><h2 class="text-base sm:text-lg md:text-xl font-semibold text-medical-gray-800 pr-4 leading-tight card-title-responsive">WARNINGS AND PRECAUTIONS</h2><div class="flex-shrink-0 mt-1"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-chevron-up text-medical-gray-400 h-4 w-4 sm:h-5 sm:w-5"><path d="m18 15-6-6-6 6"></path></svg></div></button><div class="p-6 px-4 sm:px-6 pb-4 sm:pb-6 pt-0"><div class="prose max-w-none"><p><strong>Pancreatitis:</strong> Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists.</p></div></div></div><div class="rounded-lg border bg-card text-card-foreground shadow-sm mb-8" id="adverse-reactions"><button class="gap-2 whitespace-nowrap text-sm font-medium ring-offset-background transition-colors focus-visible:outline-none focus-visible:ring-2 focus-visible:ring-ring focus-visible:ring-offset-2 disabled:pointer-events-none disabled:opacity-50 [&amp;_svg]:pointer-events-none [&amp;_svg]:size-4 [&amp;_svg]:shrink-0 hover:text-accent-foreground h-10 w-full flex items-start justify-between p-4 sm:p-6 text-left hover:bg-gray-50 rounded-none min-h-[60px]"><h2 class="text-base sm:text-lg md:text-xl font-semibold text-medical-gray-800 pr-4 leading-tight card-title-responsive">ADVERSE REACTIONS</h2><div class="flex-shrink-0 mt-1"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-chevron-up text-medical-gray-400 h-4 w-4 sm:h-5 sm:w-5"><path d="m18 15-6-6-6 6"></path></svg></div></button><div class="p-6 px-4 sm:px-6 pb-4 sm:pb-6 pt-0"><div class="prose max-w-none"><p>The most common adverse reactions reported in ≥5% of patients treated with MOUNJARO are nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, and abdominal pain.</p></div></div></div><div class="rounded-lg border bg-card text-card-foreground shadow-sm mb-8" id="drug-interactions"><button class="gap-2 whitespace-nowrap text-sm font-medium ring-offset-background transition-colors focus-visible:outline-none focus-visible:ring-2 focus-visible:ring-ring focus-visible:ring-offset-2 disabled:pointer-events-none disabled:opacity-50 [&amp;_svg]:pointer-events-none [&amp;_svg]:size-4 [&amp;_svg]:shrink-0 hover:text-accent-foreground h-10 w-full flex items-start justify-between p-4 sm:p-6 text-left hover:bg-gray-50 rounded-none min-h-[60px]"><h2 class="text-base sm:text-lg md:text-xl font-semibold text-medical-gray-800 pr-4 leading-tight card-title-responsive">DRUG INTERACTIONS</h2><div class="flex-shrink-0 mt-1"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-chevron-up text-medical-gray-400 h-4 w-4 sm:h-5 sm:w-5"><path d="m18 15-6-6-6 6"></path></svg></div></button><div class="p-6 px-4 sm:px-6 pb-4 sm:pb-6 pt-0"><div class="prose max-w-none"><p>MOUNJARO delays gastric emptying, and thereby has the potential to impact the absorption of concomitantly administered oral medications.</p></div></div></div><div class="rounded-lg border bg-card text-card-foreground shadow-sm mb-8" id="clinical-pharmacology"><button class="gap-2 whitespace-nowrap text-sm font-medium ring-offset-background transition-colors focus-visible:outline-none focus-visible:ring-2 focus-visible:ring-ring focus-visible:ring-offset-2 disabled:pointer-events-none disabled:opacity-50 [&amp;_svg]:pointer-events-none [&amp;_svg]:size-4 [&amp;_svg]:shrink-0 hover:text-accent-foreground h-10 w-full flex items-start justify-between p-4 sm:p-6 text-left hover:bg-gray-50 rounded-none min-h-[60px]"><h2 class="text-base sm:text-lg md:text-xl font-semibold text-medical-gray-800 pr-4 leading-tight card-title-responsive">CLINICAL PHARMACOLOGY</h2><div class="flex-shrink-0 mt-1"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-chevron-up text-medical-gray-400 h-4 w-4 sm:h-5 sm:w-5"><path d="m18 15-6-6-6 6"></path></svg></div></button><div class="p-6 px-4 sm:px-6 pb-4 sm:pb-6 pt-0"><div class="prose max-w-none"><p>Tirzepatide is a 39-amino-acid modified peptide with a C20 fatty diacid moiety that enables albumin binding and prolongs the half-life.</p></div></div></div><div class="rounded-lg border bg-card text-card-foreground shadow-sm mb-8" id="nonclinical-toxicology"><button class="gap-2 whitespace-nowrap text-sm font-medium ring-offset-background transition-colors focus-visible:outline-none focus-visible:ring-2 focus-visible:ring-ring focus-visible:ring-offset-2 disabled:pointer-events-none disabled:opacity-50 [&amp;_svg]:pointer-events-none [&amp;_svg]:size-4 [&amp;_svg]:shrink-0 hover:text-accent-foreground h-10 w-full flex items-start justify-between p-4 sm:p-6 text-left hover:bg-gray-50 rounded-none min-h-[60px]"><h2 class="text-base sm:text-lg md:text-xl font-semibold text-medical-gray-800 pr-4 leading-tight card-title-responsive">NONCLINICAL TOXICOLOGY</h2><div class="flex-shrink-0 mt-1"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-chevron-up text-medical-gray-400 h-4 w-4 sm:h-5 sm:w-5"><path d="m18 15-6-6-6 6"></path></svg></div></button><div class="p-6 px-4 sm:px-6 pb-4 sm:pb-6 pt-0"><div class="prose max-w-none"><p>In a 2-year carcinogenicity study in rats, tirzepatide caused a dose-related and treatment-duration-dependent increase in the incidence of thyroid C-cell adenomas and carcinomas.</p></div></div></div><div class="rounded-lg border bg-card text-card-foreground shadow-sm mb-8" id="clinical-studies"><button class="gap-2 whitespace-nowrap text-sm font-medium ring-offset-background transition-colors focus-visible:outline-none focus-visible:ring-2 focus-visible:ring-ring focus-visible:ring-offset-2 disabled:pointer-events-none disabled:opacity-50 [&amp;_svg]:pointer-events-none [&amp;_svg]:size-4 [&amp;_svg]:shrink-0 hover:text-accent-foreground h-10 w-full flex items-start justify-between p-4 sm:p-6 text-left hover:bg-gray-50 rounded-none min-h-[60px]"><h2 class="text-base sm:text-lg md:text-xl font-semibold text-medical-gray-800 pr-4 leading-tight card-title-responsive">CLINICAL STUDIES</h2><div class="flex-shrink-0 mt-1"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-chevron-up text-medical-gray-400 h-4 w-4 sm:h-5 sm:w-5"><path d="m18 15-6-6-6 6"></path></svg></div></button><div class="p-6 px-4 sm:px-6 pb-4 sm:pb-6 pt-0"><div class="prose max-w-none"><p>The efficacy of MOUNJARO was evaluated in five multicenter, randomized, controlled trials in adult patients with type 2 diabetes.</p></div></div></div><div class="rounded-lg border bg-card text-card-foreground shadow-sm mb-8" id="description"><button class="gap-2 whitespace-nowrap text-sm font-medium ring-offset-background transition-colors focus-visible:outline-none focus-visible:ring-2 focus-visible:ring-ring focus-visible:ring-offset-2 disabled:pointer-events-none disabled:opacity-50 [&amp;_svg]:pointer-events-none [&amp;_svg]:size-4 [&amp;_svg]:shrink-0 hover:text-accent-foreground h-10 w-full flex items-start justify-between p-4 sm:p-6 text-left hover:bg-gray-50 rounded-none min-h-[60px]"><h2 class="text-base sm:text-lg md:text-xl font-semibold text-medical-gray-800 pr-4 leading-tight card-title-responsive">DESCRIPTION</h2><div class="flex-shrink-0 mt-1"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-chevron-up text-medical-gray-400 h-4 w-4 sm:h-5 sm:w-5"><path d="m18 15-6-6-6 6"></path></svg></div></button><div class="p-6 px-4 sm:px-6 pb-4 sm:pb-6 pt-0"><div class="prose max-w-none"><p>MOUNJARO contains tirzepatide, a GIP receptor and GLP-1 receptor agonist. It is a 39-amino-acid modified peptide.</p></div></div></div><div class="rounded-lg border bg-card text-card-foreground shadow-sm mb-8" id="how-supplied"><button class="gap-2 whitespace-nowrap text-sm font-medium ring-offset-background transition-colors focus-visible:outline-none focus-visible:ring-2 focus-visible:ring-ring focus-visible:ring-offset-2 disabled:pointer-events-none disabled:opacity-50 [&amp;_svg]:pointer-events-none [&amp;_svg]:size-4 [&amp;_svg]:shrink-0 hover:text-accent-foreground h-10 w-full flex items-start justify-between p-4 sm:p-6 text-left hover:bg-gray-50 rounded-none min-h-[60px]"><h2 class="text-base sm:text-lg md:text-xl font-semibold text-medical-gray-800 pr-4 leading-tight card-title-responsive">HOW SUPPLIED/STORAGE AND HANDLING</h2><div class="flex-shrink-0 mt-1"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-chevron-up text-medical-gray-400 h-4 w-4 sm:h-5 sm:w-5"><path d="m18 15-6-6-6 6"></path></svg></div></button><div class="p-6 px-4 sm:px-6 pb-4 sm:pb-6 pt-0"><div class="prose max-w-none"><p>MOUNJARO is supplied as a single-dose pen containing a 0.5 mL solution in the following dosage strengths: 2.5 mg/0.5 mL, 5 mg/0.5 mL, 7.5 mg/0.5 mL, 10 mg/0.5 mL, 12.5 mg/0.5 mL, and 15 mg/0.5 mL.</p></div></div></div><div class="rounded-lg border bg-card text-card-foreground shadow-sm mb-8" id="patient-counseling"><button class="gap-2 whitespace-nowrap text-sm font-medium ring-offset-background transition-colors focus-visible:outline-none focus-visible:ring-2 focus-visible:ring-ring focus-visible:ring-offset-2 disabled:pointer-events-none disabled:opacity-50 [&amp;_svg]:pointer-events-none [&amp;_svg]:size-4 [&amp;_svg]:shrink-0 hover:text-accent-foreground h-10 w-full flex items-start justify-between p-4 sm:p-6 text-left hover:bg-gray-50 rounded-none min-h-[60px]"><h2 class="text-base sm:text-lg md:text-xl font-semibold text-medical-gray-800 pr-4 leading-tight card-title-responsive">PATIENT COUNSELING INFORMATION</h2><div class="flex-shrink-0 mt-1"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-chevron-up text-medical-gray-400 h-4 w-4 sm:h-5 sm:w-5"><path d="m18 15-6-6-6 6"></path></svg></div></button><div class="p-6 px-4 sm:px-6 pb-4 sm:pb-6 pt-0"><div class="prose max-w-none"><p>Advise the patient to read the FDA-approved patient labeling (Medication Guide and Instructions for Use).</p></div></div></div><div class="rounded-lg border bg-card text-card-foreground shadow-sm mb-8" id="overdosage"><button class="gap-2 whitespace-nowrap text-sm font-medium ring-offset-background transition-colors focus-visible:outline-none focus-visible:ring-2 focus-visible:ring-ring focus-visible:ring-offset-2 disabled:pointer-events-none disabled:opacity-50 [&amp;_svg]:pointer-events-none [&amp;_svg]:size-4 [&amp;_svg]:shrink-0 hover:text-accent-foreground h-10 w-full flex items-start justify-between p-4 sm:p-6 text-left hover:bg-gray-50 rounded-none min-h-[60px]"><h2 class="text-base sm:text-lg md:text-xl font-semibold text-medical-gray-800 pr-4 leading-tight card-title-responsive">OVERDOSAGE</h2><div class="flex-shrink-0 mt-1"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-chevron-up text-medical-gray-400 h-4 w-4 sm:h-5 sm:w-5"><path d="m18 15-6-6-6 6"></path></svg></div></button><div class="p-6 px-4 sm:px-6 pb-4 sm:pb-6 pt-0"><div class="prose max-w-none"><p>In the event of overdosage, contact Poison Control for latest recommendations. Based on the pharmacological actions of tirzepatide, an overdose may result in gastrointestinal adverse reactions and hypoglycemia.</p></div></div></div><div class="rounded-lg border bg-card text-card-foreground shadow-sm mb-8" id="principal-display-panel"><button class="gap-2 whitespace-nowrap text-sm font-medium ring-offset-background transition-colors focus-visible:outline-none focus-visible:ring-2 focus-visible:ring-ring focus-visible:ring-offset-2 disabled:pointer-events-none disabled:opacity-50 [&amp;_svg]:pointer-events-none [&amp;_svg]:size-4 [&amp;_svg]:shrink-0 hover:text-accent-foreground h-10 w-full flex items-start justify-between p-4 sm:p-6 text-left hover:bg-gray-50 rounded-none min-h-[60px]"><h2 class="text-base sm:text-lg md:text-xl font-semibold text-medical-gray-800 pr-4 leading-tight card-title-responsive">PRINCIPAL DISPLAY PANEL</h2><div class="flex-shrink-0 mt-1"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-chevron-up text-medical-gray-400 h-4 w-4 sm:h-5 sm:w-5"><path d="m18 15-6-6-6 6"></path></svg></div></button><div class="p-6 px-4 sm:px-6 pb-4 sm:pb-6 pt-0"><div class="prose max-w-none"><p>NDC 0002-1434-80<br/>MOUNJARO™<br/>(tirzepatide) injection<br/>2.5 mg/0.5 mL<br/>For subcutaneous use only<br/>Single-Dose Pen<br/>Rx only</p></div></div></div></div><div data-state="inactive" data-orientation="horizontal" role="tabpanel" aria-labelledby="radix-_R_4lfiv5udb_-trigger-patient" hidden="" id="radix-_R_4lfiv5udb_-content-patient" tabindex="0" class="ring-offset-background focus-visible:outline-none focus-visible:ring-2 focus-visible:ring-ring focus-visible:ring-offset-2 space-y-4 sm:space-y-6 mt-4 sm:mt-6"></div><div data-state="inactive" data-orientation="horizontal" role="tabpanel" aria-labelledby="radix-_R_4lfiv5udb_-trigger-faq" hidden="" id="radix-_R_4lfiv5udb_-content-faq" tabindex="0" class="ring-offset-background focus-visible:outline-none focus-visible:ring-2 focus-visible:ring-ring focus-visible:ring-offset-2 space-y-4 sm:space-y-6 mt-4 sm:mt-6"></div></div></div><div class="lg:col-span-1"><div class="rounded-lg border bg-card text-card-foreground shadow-sm p-4 sm:p-6 sticky top-4 sm:top-8"><h3 class="font-semibold mb-4">Drug Information</h3><dl class="space-y-3 text-sm"><dt class="text-gray-600">Drug Name</dt><dd class="font-medium">Mounjaro</dd><dt class="text-gray-600 mt-3">Generic Name</dt><dd class="font-medium">tirzepatide</dd><dt class="text-gray-600 mt-3">Set ID</dt><dd class="font-medium font-mono text-xs">d2d7da5d-ad07-4228-955f-cf7e355c8cc0</dd><dt class="text-gray-600 mt-3">Labeler</dt><dd class="font-medium">Eli Lilly and Company</dd><dt class="text-gray-600 mt-3">Therapeutic Class</dt><dd class="font-medium">GLP-1/GIP Receptor Agonist</dd><dt class="text-gray-600 mt-3">Active Ingredient</dt><dd class="font-medium">tirzepatide</dd><dt class="text-gray-600 mt-3">Manufacturer</dt><dd class="font-medium">Eli Lilly and Company</dd><dt class="text-gray-600 mt-3">Slug</dt><dd class="font-medium text-xs text-gray-500">mounjaro-d2d7da5</dd></dl></div></div></div></div><!--$--><!--/$--></main><footer class="bg-medical-gray-800 text-medical-gray-300 mt-16"><div class="max-w-7xl mx-auto px-4 sm:px-6 lg:px-8 py-12"><div class="grid grid-cols-1 md:grid-cols-4 gap-8"><div><h3 class="text-lg font-semibold text-white mb-4">drugfacts.wiki</h3><p class="text-sm">Comprehensive FDA drug information for healthcare professionals</p></div><div><h4 class="font-semibold text-white mb-3">Resources</h4><ul class="space-y-2 text-sm"><li><a class="hover:text-white transition-colors" href="/search/">Drug Search</a></li><li><a class="hover:text-white transition-colors" href="/therapeutic-classes/">Therapeutic Classes</a></li><li><a class="hover:text-white transition-colors" href="/interactions/">Drug Interactions</a></li></ul></div><div><h4 class="font-semibold text-white mb-3">Support</h4><ul class="space-y-2 text-sm"><li><a class="hover:text-white transition-colors" href="/contact/">Contact Us</a></li><li><a class="hover:text-white transition-colors" href="/faq/">FAQ</a></li><li><a class="hover:text-white transition-colors" href="/terms/">Terms of Service</a></li></ul></div><div><h4 class="font-semibold text-white mb-3">Legal</h4><ul class="space-y-2 text-sm"><li><a class="hover:text-white transition-colors" href="/privacy/">Privacy Policy</a></li><li><a class="hover:text-white transition-colors" href="/disclaimer/">Disclaimer</a></li><li><a class="hover:text-white transition-colors" href="/accessibility/">Accessibility</a></li></ul></div></div><div class="border-t border-medical-gray-700 mt-8 pt-8 text-center text-sm"><p>© 2025 drugfacts.wiki. All rights reserved. This information is for healthcare professionals only.</p></div></div></footer></div><div role="region" aria-label="Notifications (F8)" tabindex="-1" style="pointer-events:none"><ol tabindex="-1" class="fixed top-0 z-[100] flex max-h-screen w-full flex-col-reverse p-4 sm:bottom-0 sm:right-0 sm:top-auto sm:flex-col md:max-w-[420px]"></ol></div><script src="/_next/static/chunks/webpack-86b9a0a63f5f9169.js" id="_R_" async=""></script><script>(self.__next_f=self.__next_f||[]).push([0])</script><script>self.__next_f.push([1,"1:\"$Sreact.fragment\"\n2:I[9881,[\"874\",\"static/chunks/874-437a265a67d6cfee.js\",\"455\",\"static/chunks/455-28b7fbb360ee31f4.js\",\"187\",\"static/chunks/187-9968f21ecf164052.js\",\"177\",\"static/chunks/app/layout-fa7cba4b34f22bd9.js\"],\"default\"]\n3:I[7555,[],\"\"]\n4:I[1295,[],\"\"]\n5:I[6874,[\"874\",\"static/chunks/874-437a265a67d6cfee.js\",\"455\",\"static/chunks/455-28b7fbb360ee31f4.js\",\"496\",\"static/chunks/496-4ec65330a7ffa1d1.js\",\"42\",\"static/chunks/app/drugs/%5Bslug%5D/page-92c303eaeef28156.js\"],\"\"]\ne:I[8393,[],\"\"]\n:HL[\"/_next/static/media/e4af272ccee01ff0-s.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/css/5884bd3aaf456fca.css\",\"style\"]\n:HL[\"/_next/static/css/931b179cff3131dc.css\",\"style\"]\n"])</script><script>self.__next_f.push([1,"0:{\"P\":null,\"b\":\"Xd76CUF9_ROIgMmQRWBvv\",\"p\":\"\",\"c\":[\"\",\"drugs\",\"mounjaro-d2d7da5\",\"\"],\"i\":false,\"f\":[[[\"\",{\"children\":[\"drugs\",{\"children\":[[\"slug\",\"mounjaro-d2d7da5\",\"d\"],{\"children\":[\"__PAGE__\",{}]}]}]},\"$undefined\",\"$undefined\",true],[\"\",[\"$\",\"$1\",\"c\",{\"children\":[[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/5884bd3aaf456fca.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"$undefined\"}],[\"$\",\"link\",\"1\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/931b179cff3131dc.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"$undefined\"}]],[\"$\",\"html\",null,{\"lang\":\"en\",\"data-scroll-behavior\":\"smooth\",\"children\":[[\"$\",\"head\",null,{\"children\":[[\"$\",\"link\",null,{\"rel\":\"dns-prefetch\",\"href\":\"//fonts.googleapis.com\"}],[\"$\",\"link\",null,{\"rel\":\"preconnect\",\"href\":\"https://fonts.googleapis.com\",\"crossOrigin\":\"anonymous\"}],[\"$\",\"link\",null,{\"rel\":\"preload\",\"href\":\"/og-image.png\",\"as\":\"image\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"type\":\"image/x-icon\",\"href\":\"/favicon.ico\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"type\":\"image/png\",\"sizes\":\"32x32\",\"href\":\"/og-image.png\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"type\":\"image/png\",\"sizes\":\"16x16\",\"href\":\"/og-image.png\"}],[\"$\",\"link\",null,{\"rel\":\"apple-touch-icon\",\"href\":\"/og-image.png\"}],[\"$\",\"meta\",null,{\"name\":\"theme-color\",\"content\":\"#3B82F6\"}],[\"$\",\"link\",null,{\"rel\":\"manifest\",\"href\":\"/manifest.json\"}]]}],[\"$\",\"body\",null,{\"className\":\"__className_e8ce0c\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex min-h-screen flex-col\",\"children\":[[\"$\",\"$L2\",null,{}],[\"$\",\"main\",null,{\"className\":\"flex-1\",\"role\":\"main\",\"children\":[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[\"$\",\"div\",null,{\"className\":\"container mx-auto px-4 py-16\",\"children\":[\"$\",\"div\",null,{\"className\":\"max-w-2xl mx-auto\",\"children\":[\"$\",\"div\",null,{\"ref\":\"$undefined\",\"className\":\"rounded-lg border bg-card text-card-foreground shadow-sm\",\"children\":[[\"$\",\"div\",null,{\"ref\":\"$undefined\",\"className\":\"flex flex-col space-y-1.5 p-6 text-center\",\"children\":[[\"$\",\"div\",null,{\"ref\":\"$undefined\",\"className\":\"tracking-tight text-6xl font-bold text-gray-300\",\"children\":\"404\"}],[\"$\",\"div\",null,{\"ref\":\"$undefined\",\"className\":\"text-muted-foreground text-xl mt-4\",\"children\":\"Page Not Found\"}]]}],[\"$\",\"div\",null,{\"ref\":\"$undefined\",\"className\":\"p-6 pt-0 text-center space-y-6\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-gray-600\",\"children\":\"The page you're looking for doesn't exist or has been moved.\"}],[\"$\",\"div\",null,{\"className\":\"flex flex-col sm:flex-row gap-4 justify-center\",\"children\":[[\"$\",\"$L5\",null,{\"href\":\"/\",\"children\":[\"$\",\"button\",null,{\"className\":\"inline-flex items-center justify-center gap-2 whitespace-nowrap rounded-md text-sm font-medium ring-offset-background transition-colors focus-visible:outline-none focus-visible:ring-2 focus-visible:ring-ring focus-visible:ring-offset-2 disabled:pointer-events-none disabled:opacity-50 [\u0026_svg]:pointer-events-none [\u0026_svg]:size-4 [\u0026_svg]:shrink-0 bg-primary text-primary-foreground hover:bg-primary/90 h-10 px-4 py-2 w-full sm:w-auto\",\"ref\":\"$undefined\",\"children\":[[\"$\",\"svg\",null,{\"ref\":\"$undefined\",\"xmlns\":\"http://www.w3.org/2000/svg\",\"width\":24,\"height\":24,\"viewBox\":\"0 0 24 24\",\"fill\":\"none\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"className\":\"lucide lucide-house mr-2 h-4 w-4\",\"children\":[[\"$\",\"path\",\"5wwlr5\",{\"d\":\"M15 21v-8a1 1 0 0 0-1-1h-4a1 1 0 0 0-1 1v8\"}],[\"$\",\"path\",\"1d0kgt\",{\"d\":\"M3 10a2 2 0 0 1 .709-1.528l7-5.999a2 2 0 0 1 2.582 0l7 5.999A2 2 0 0 1 21 10v9a2 2 0 0 1-2 2H5a2 2 0 0 1-2-2z\"}],\"$undefined\"]}],\"Go Home\"]}]}],[\"$\",\"$L5\",null,{\"href\":\"/search\",\"children\":[\"$\",\"button\",null,{\"className\":\"inline-flex items-center justify-center gap-2 whitespace-nowrap rounded-md text-sm font-medium ring-offset-background transition-colors focus-visible:outline-none focus-visible:ring-2 focus-visible:ring-ring focus-visible:ring-offset-2 disabled:pointer-events-none disabled:opacity-50 [\u0026_svg]:pointer-events-none [\u0026_svg]:size-4 [\u0026_svg]:shrink-0 border border-input bg-background hover:bg-accent hover:text-accent-foreground h-10 px-4 py-2 w-full sm:w-auto\",\"ref\":\"$undefined\",\"children\":[[\"$\",\"svg\",null,{\"ref\":\"$undefined\",\"xmlns\":\"http://www.w3.org/2000/svg\",\"width\":24,\"height\":24,\"viewBox\":\"0 0 24 24\",\"fill\":\"none\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"className\":\"lucide lucide-search mr-2 h-4 w-4\",\"children\":[\"$L6\",\"$L7\",\"$undefined\"]}],\"Search Drugs\"]}]}]]}]]}]]}]}]}],[]],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]}],\"$L8\"]}],\"$L9\"]}]]}]]}],{\"children\":[\"drugs\",\"$La\",{\"children\":[[\"slug\",\"mounjaro-d2d7da5\",\"d\"],\"$Lb\",{\"children\":[\"__PAGE__\",\"$Lc\",{},null,false]},null,false]},null,false]},null,false],\"$Ld\",false]],\"m\":\"$undefined\",\"G\":[\"$e\",[]],\"s\":false,\"S\":true}\n"])</script><script>self.__next_f.push([1,"f:I[6471,[\"874\",\"static/chunks/874-437a265a67d6cfee.js\",\"455\",\"static/chunks/455-28b7fbb360ee31f4.js\",\"187\",\"static/chunks/187-9968f21ecf164052.js\",\"177\",\"static/chunks/app/layout-fa7cba4b34f22bd9.js\"],\"Toaster\"]\n11:I[9665,[],\"OutletBoundary\"]\n13:I[4911,[],\"AsyncMetadataOutlet\"]\n15:I[9665,[],\"ViewportBoundary\"]\n17:I[9665,[],\"MetadataBoundary\"]\n18:\"$Sreact.suspense\"\n6:[\"$\",\"circle\",\"4ej97u\",{\"cx\":\"11\",\"cy\":\"11\",\"r\":\"8\"}]\n7:[\"$\",\"path\",\"1qie3q\",{\"d\":\"m21 21-4.3-4.3\"}]\n"])</script><script>self.__next_f.push([1,"8:[\"$\",\"footer\",null,{\"className\":\"bg-medical-gray-800 text-medical-gray-300 mt-16\",\"children\":[\"$\",\"div\",null,{\"className\":\"max-w-7xl mx-auto px-4 sm:px-6 lg:px-8 py-12\",\"children\":[[\"$\",\"div\",null,{\"className\":\"grid grid-cols-1 md:grid-cols-4 gap-8\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"h3\",null,{\"className\":\"text-lg font-semibold text-white mb-4\",\"children\":\"drugfacts.wiki\"}],[\"$\",\"p\",null,{\"className\":\"text-sm\",\"children\":\"Comprehensive FDA drug information for healthcare professionals\"}]]}],[[\"$\",\"div\",\"Resources\",{\"children\":[[\"$\",\"h4\",null,{\"className\":\"font-semibold text-white mb-3\",\"children\":\"Resources\"}],[\"$\",\"ul\",null,{\"className\":\"space-y-2 text-sm\",\"children\":[[\"$\",\"li\",\"Drug Search\",{\"children\":[\"$\",\"$L5\",null,{\"href\":\"/search\",\"className\":\"hover:text-white transition-colors\",\"children\":\"Drug Search\"}]}],[\"$\",\"li\",\"Therapeutic Classes\",{\"children\":[\"$\",\"$L5\",null,{\"href\":\"/therapeutic-classes\",\"className\":\"hover:text-white transition-colors\",\"children\":\"Therapeutic Classes\"}]}],[\"$\",\"li\",\"Drug Interactions\",{\"children\":[\"$\",\"$L5\",null,{\"href\":\"/interactions\",\"className\":\"hover:text-white transition-colors\",\"children\":\"Drug Interactions\"}]}]]}]]}],[\"$\",\"div\",\"Support\",{\"children\":[[\"$\",\"h4\",null,{\"className\":\"font-semibold text-white mb-3\",\"children\":\"Support\"}],[\"$\",\"ul\",null,{\"className\":\"space-y-2 text-sm\",\"children\":[[\"$\",\"li\",\"Contact Us\",{\"children\":[\"$\",\"$L5\",null,{\"href\":\"/contact\",\"className\":\"hover:text-white transition-colors\",\"children\":\"Contact Us\"}]}],[\"$\",\"li\",\"FAQ\",{\"children\":[\"$\",\"$L5\",null,{\"href\":\"/faq\",\"className\":\"hover:text-white transition-colors\",\"children\":\"FAQ\"}]}],[\"$\",\"li\",\"Terms of Service\",{\"children\":[\"$\",\"$L5\",null,{\"href\":\"/terms\",\"className\":\"hover:text-white transition-colors\",\"children\":\"Terms of Service\"}]}]]}]]}],[\"$\",\"div\",\"Legal\",{\"children\":[[\"$\",\"h4\",null,{\"className\":\"font-semibold text-white mb-3\",\"children\":\"Legal\"}],[\"$\",\"ul\",null,{\"className\":\"space-y-2 text-sm\",\"children\":[[\"$\",\"li\",\"Privacy Policy\",{\"children\":[\"$\",\"$L5\",null,{\"href\":\"/privacy\",\"className\":\"hover:text-white transition-colors\",\"children\":\"Privacy Policy\"}]}],[\"$\",\"li\",\"Disclaimer\",{\"children\":[\"$\",\"$L5\",null,{\"href\":\"/disclaimer\",\"className\":\"hover:text-white transition-colors\",\"children\":\"Disclaimer\"}]}],[\"$\",\"li\",\"Accessibility\",{\"children\":[\"$\",\"$L5\",null,{\"href\":\"/accessibility\",\"className\":\"hover:text-white transition-colors\",\"children\":\"Accessibility\"}]}]]}]]}]]]}],[\"$\",\"div\",null,{\"className\":\"border-t border-medical-gray-700 mt-8 pt-8 text-center text-sm\",\"children\":[\"$\",\"p\",null,{\"children\":\"© 2025 drugfacts.wiki. All rights reserved. This information is for healthcare professionals only.\"}]}]]}]}]\n"])</script><script>self.__next_f.push([1,"9:[\"$\",\"$Lf\",null,{}]\na:[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$undefined\",\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}]\nb:[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$undefined\",\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}]\nc:[\"$\",\"$1\",\"c\",{\"children\":[\"$L10\",null,[\"$\",\"$L11\",null,{\"children\":[\"$L12\",[\"$\",\"$L13\",null,{\"promise\":\"$@14\"}]]}]]}]\nd:[\"$\",\"$1\",\"h\",{\"children\":[null,[[\"$\",\"$L15\",null,{\"children\":\"$L16\"}],[\"$\",\"meta\",null,{\"name\":\"next-size-adjust\",\"content\":\"\"}]],[\"$\",\"$L17\",null,{\"children\":[\"$\",\"div\",null,{\"hidden\":true,\"children\":[\"$\",\"$18\",null,{\"fallback\":null,\"children\":\"$L19\"}]}]}]]}]\n"])</script><script>self.__next_f.push([1,"16:[[\"$\",\"meta\",\"0\",{\"charSet\":\"utf-8\"}],[\"$\",\"meta\",\"1\",{\"name\":\"viewport\",\"content\":\"width=device-width, initial-scale=1\"}]]\n12:null\n"])</script><script>self.__next_f.push([1,"14:{\"metadata\":[[\"$\",\"title\",\"0\",{\"children\":\"Mounjaro (tirzepatide) | drugfacts.wiki\"}],[\"$\",\"meta\",\"1\",{\"name\":\"description\",\"content\":\"Complete prescribing information for Mounjaro (tirzepatide). Diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Dosing, s...\"}],[\"$\",\"meta\",\"2\",{\"name\":\"author\",\"content\":\"drugfacts.wiki\"}],[\"$\",\"meta\",\"3\",{\"name\":\"keywords\",\"content\":\"mounjaro, tirzepatide, glp-1/gip receptor agonist, prescribing information, drug facts, medical information, diabetes\"}],[\"$\",\"meta\",\"4\",{\"name\":\"robots\",\"content\":\"index, follow\"}],[\"$\",\"meta\",\"5\",{\"name\":\"googlebot\",\"content\":\"index, follow, max-video-preview:-1, max-image-preview:large, max-snippet:-1\"}],[\"$\",\"meta\",\"6\",{\"property\":\"og:title\",\"content\":\"Mounjaro - Professional Drug Information\"}],[\"$\",\"meta\",\"7\",{\"property\":\"og:description\",\"content\":\"Diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Complete prescribing information including dosing, contraindications, and safety data.\"}],[\"$\",\"meta\",\"8\",{\"property\":\"og:site_name\",\"content\":\"drugfacts.wiki\"}],[\"$\",\"meta\",\"9\",{\"property\":\"og:type\",\"content\":\"article\"}],[\"$\",\"meta\",\"10\",{\"name\":\"twitter:card\",\"content\":\"summary_large_image\"}],[\"$\",\"meta\",\"11\",{\"name\":\"twitter:title\",\"content\":\"Mounjaro - Professional Drug Information\"}],[\"$\",\"meta\",\"12\",{\"name\":\"twitter:description\",\"content\":\"Diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Complete prescribing information including dosing, contraindications, and safety data.\"}]],\"error\":null,\"digest\":\"$undefined\"}\n"])</script><script>self.__next_f.push([1,"19:\"$14:metadata\"\n"])</script><script>self.__next_f.push([1,"1a:I[2581,[\"874\",\"static/chunks/874-437a265a67d6cfee.js\",\"455\",\"static/chunks/455-28b7fbb360ee31f4.js\",\"496\",\"static/chunks/496-4ec65330a7ffa1d1.js\",\"42\",\"static/chunks/app/drugs/%5Bslug%5D/page-92c303eaeef28156.js\"],\"default\"]\n1b:I[64,[\"874\",\"static/chunks/874-437a265a67d6cfee.js\",\"455\",\"static/chunks/455-28b7fbb360ee31f4.js\",\"496\",\"static/chunks/496-4ec65330a7ffa1d1.js\",\"42\",\"static/chunks/app/drugs/%5Bslug%5D/page-92c303eaeef28156.js\"],\"Root\"]\n"])</script><script>self.__next_f.push([1,"10:[\"$\",\"div\",null,{\"className\":\"container mx-auto px-2 sm:px-4 py-4 sm:py-8\",\"children\":[\"$\",\"div\",null,{\"className\":\"grid grid-cols-1 lg:grid-cols-4 gap-4 lg:gap-8\",\"children\":[[\"$\",\"div\",null,{\"className\":\"lg:col-span-3\",\"children\":[[\"$\",\"$L1a\",null,{\"drug\":{\"drugName\":\"Mounjaro\",\"genericName\":\"tirzepatide\",\"slug\":\"mounjaro-d2d7da5\",\"setId\":\"d2d7da5d-ad07-4228-955f-cf7e355c8cc0\",\"activeIngredient\":\"tirzepatide\",\"therapeuticClass\":\"GLP-1/GIP Receptor Agonist\",\"manufacturer\":\"Eli Lilly and Company\",\"boxedWarning\":\"\u003cp\u003e\u003cstrong\u003eWARNING: RISK OF THYROID C-CELL TUMORS\u003c/strong\u003e\u003c/p\u003e\u003cp\u003eIn rodents, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors. It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans.\u003c/p\u003e\",\"indicationsAndUsage\":\"\u003cp\u003eMOUNJARO is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.\u003c/p\u003e\",\"dosageAndAdministration\":\"\u003cp\u003eThe recommended starting dosage of MOUNJARO is 2.5 mg injected subcutaneously once weekly. After 4 weeks, increase the dosage to 5 mg injected subcutaneously once weekly.\u003c/p\u003e\",\"contraindications\":\"\u003cp\u003eMOUNJARO is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2.\u003c/p\u003e\",\"warnings\":\"\u003cp\u003e\u003cstrong\u003ePancreatitis:\u003c/strong\u003e Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists.\u003c/p\u003e\",\"adverseReactions\":\"\u003cp\u003eThe most common adverse reactions reported in ≥5% of patients treated with MOUNJARO are nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, and abdominal pain.\u003c/p\u003e\",\"drugInteractions\":\"\u003cp\u003eMOUNJARO delays gastric emptying, and thereby has the potential to impact the absorption of concomitantly administered oral medications.\u003c/p\u003e\",\"clinicalPharmacology\":\"\u003cp\u003eTirzepatide is a 39-amino-acid modified peptide with a C20 fatty diacid moiety that enables albumin binding and prolongs the half-life.\u003c/p\u003e\",\"clinicalStudies\":\"\u003cp\u003eThe efficacy of MOUNJARO was evaluated in five multicenter, randomized, controlled trials in adult patients with type 2 diabetes.\u003c/p\u003e\",\"howSupplied\":\"\u003cp\u003eMOUNJARO is supplied as a single-dose pen containing a 0.5 mL solution in the following dosage strengths: 2.5 mg/0.5 mL, 5 mg/0.5 mL, 7.5 mg/0.5 mL, 10 mg/0.5 mL, 12.5 mg/0.5 mL, and 15 mg/0.5 mL.\u003c/p\u003e\",\"patientCounseling\":\"\u003cp\u003eAdvise the patient to read the FDA-approved patient labeling (Medication Guide and Instructions for Use).\u003c/p\u003e\",\"description\":\"\u003cp\u003eMOUNJARO contains tirzepatide, a GIP receptor and GLP-1 receptor agonist. It is a 39-amino-acid modified peptide.\u003c/p\u003e\",\"overdosage\":\"\u003cp\u003eIn the event of overdosage, contact Poison Control for latest recommendations. Based on the pharmacological actions of tirzepatide, an overdose may result in gastrointestinal adverse reactions and hypoglycemia.\u003c/p\u003e\",\"nonClinicalToxicology\":\"\u003cp\u003eIn a 2-year carcinogenicity study in rats, tirzepatide caused a dose-related and treatment-duration-dependent increase in the incidence of thyroid C-cell adenomas and carcinomas.\u003c/p\u003e\",\"principalDisplayPanel\":\"\u003cp\u003eNDC 0002-1434-80\u003cbr/\u003eMOUNJARO™\u003cbr/\u003e(tirzepatide) injection\u003cbr/\u003e2.5 mg/0.5 mL\u003cbr/\u003eFor subcutaneous use only\u003cbr/\u003eSingle-Dose Pen\u003cbr/\u003eRx only\u003c/p\u003e\"}}],[\"$\",\"$L1b\",null,{\"defaultValue\":\"professional\",\"className\":\"mt-4 sm:mt-6\",\"children\":[\"$L1c\",\"$L1d\",\"$L1e\",\"$L1f\"]}]]}],\"$L20\"]}]}]\n"])</script><script>self.__next_f.push([1,"21:I[64,[\"874\",\"static/chunks/874-437a265a67d6cfee.js\",\"455\",\"static/chunks/455-28b7fbb360ee31f4.js\",\"496\",\"static/chunks/496-4ec65330a7ffa1d1.js\",\"42\",\"static/chunks/app/drugs/%5Bslug%5D/page-92c303eaeef28156.js\"],\"List\"]\n22:I[64,[\"874\",\"static/chunks/874-437a265a67d6cfee.js\",\"455\",\"static/chunks/455-28b7fbb360ee31f4.js\",\"496\",\"static/chunks/496-4ec65330a7ffa1d1.js\",\"42\",\"static/chunks/app/drugs/%5Bslug%5D/page-92c303eaeef28156.js\"],\"Trigger\"]\n23:I[64,[\"874\",\"static/chunks/874-437a265a67d6cfee.js\",\"455\",\"static/chunks/455-28b7fbb360ee31f4.js\",\"496\",\"static/chunks/496-4ec65330a7ffa1d1.js\",\"42\",\"static/chunks/app/drugs/%5Bslug%5D/page-92c303eaeef28156.js\"],\"Content\"]\n24:I[9717,[\"874\",\"static/chunks/874-437a265a67d6cfee.js\",\"455\",\"static/chunks/455-28b7fbb360ee31f4.js\",\"496\",\"static/chunks/496-4ec65330a7ffa1d1.js\",\"42\",\"static/chunks/app/drugs/%5Bslug%5D/page-92c303eaeef28156.js\"],\"default\"]\n2c:I[3488,[\"874\",\"static/chunks/874-437a265a67d6cfee.js\",\"455\",\"static/chunks/455-28b7fbb360ee31f4.js\",\"496\",\"static/chunks/496-4ec65330a7ffa1d1.js\",\"42\",\"static/chunks/app/drugs/%5Bslug%5D/page-92c303eaeef28156.js\"],\"default\"]\n2d:I[3474,[\"874\",\"static/chunks/874-437a265a67d6cfee.js\",\"455\",\"static/chunks/455-28b7fbb360ee31f4.js\",\"496\",\"static/chunks/496-4ec65330a7ffa1d1.js\",\"42\",\"static/chunks/app/drugs/%5Bslug%5D/page-92c303eaeef28156.js\"],\"default\"]\n2e:I[4473,[\"874\",\"static/chunks/874-437a265a67d6cfee.js\",\"455\",\"static/chunks/455-28b7fbb360ee31f4.js\",\"496\",\"static/chunks/496-4ec65330a7ffa1d1.js\",\"42\",\"static/chunks/app/drugs/%5Bslug%5D/page-92c303eaeef28156.js\"],\"default\"]\n"])</script><script>self.__next_f.push([1,"1c:[\"$\",\"$L21\",null,{\"ref\":\"$undefined\",\"className\":\"items-center justify-center text-muted-foreground flex w-full h-auto p-1 bg-gray-100 border border-gray-200 rounded-lg\",\"children\":[[\"$\",\"$L22\",null,{\"ref\":\"$undefined\",\"className\":\"inline-flex items-center justify-center whitespace-nowrap ring-offset-background focus-visible:outline-none focus-visible:ring-2 focus-visible:ring-ring focus-visible:ring-offset-2 disabled:pointer-events-none disabled:opacity-50 data-[state=active]:bg-background data-[state=active]:text-foreground text-xs sm:text-sm px-4 sm:px-6 py-3 text-center font-medium transition-all duration-200 data-[state=active]:!bg-blue-600 data-[state=active]:!text-white data-[state=active]:!border-blue-600 data-[state=active]:shadow-md data-[state=inactive]:bg-transparent data-[state=inactive]:text-gray-600 data-[state=inactive]:hover:text-blue-600 data-[state=inactive]:hover:bg-blue-50 rounded-lg border border-transparent flex-1 relative\",\"value\":\"professional\",\"children\":[[\"$\",\"span\",null,{\"className\":\"block sm:hidden\",\"children\":\"Professional\"}],[\"$\",\"span\",null,{\"className\":\"hidden sm:block\",\"children\":\"Professional Info\"}]]}],[\"$\",\"$L22\",null,{\"ref\":\"$undefined\",\"className\":\"inline-flex items-center justify-center whitespace-nowrap ring-offset-background focus-visible:outline-none focus-visible:ring-2 focus-visible:ring-ring focus-visible:ring-offset-2 disabled:pointer-events-none disabled:opacity-50 data-[state=active]:bg-background data-[state=active]:text-foreground text-xs sm:text-sm px-4 sm:px-6 py-3 text-center font-medium transition-all duration-200 data-[state=active]:!bg-blue-600 data-[state=active]:!text-white data-[state=active]:!border-blue-600 data-[state=active]:shadow-md data-[state=inactive]:bg-transparent data-[state=inactive]:text-gray-600 data-[state=inactive]:hover:text-blue-600 data-[state=inactive]:hover:bg-blue-50 rounded-lg border border-transparent flex-1 relative\",\"value\":\"patient\",\"children\":[[\"$\",\"span\",null,{\"className\":\"block sm:hidden\",\"children\":\"Patient\"}],[\"$\",\"span\",null,{\"className\":\"hidden sm:block\",\"children\":\"Patient-Friendly\"}]]}],[\"$\",\"$L22\",null,{\"ref\":\"$undefined\",\"className\":\"inline-flex items-center justify-center whitespace-nowrap ring-offset-background focus-visible:outline-none focus-visible:ring-2 focus-visible:ring-ring focus-visible:ring-offset-2 disabled:pointer-events-none disabled:opacity-50 data-[state=active]:bg-background data-[state=active]:text-foreground text-xs sm:text-sm px-4 sm:px-6 py-3 text-center font-medium transition-all duration-200 data-[state=active]:!bg-blue-600 data-[state=active]:!text-white data-[state=active]:!border-blue-600 data-[state=active]:shadow-md data-[state=inactive]:bg-transparent data-[state=inactive]:text-gray-600 data-[state=inactive]:hover:text-blue-600 data-[state=inactive]:hover:bg-blue-50 rounded-lg border border-transparent flex-1 relative\",\"value\":\"faq\",\"children\":[[\"$\",\"span\",null,{\"className\":\"block sm:hidden\",\"children\":\"FAQ\"}],[\"$\",\"span\",null,{\"className\":\"hidden sm:block\",\"children\":\"FAQ \u0026 Related\"}]]}]]}]\n"])</script><script>self.__next_f.push([1,"1d:[\"$\",\"$L23\",null,{\"ref\":\"$undefined\",\"className\":\"ring-offset-background focus-visible:outline-none focus-visible:ring-2 focus-visible:ring-ring focus-visible:ring-offset-2 space-y-4 sm:space-y-6 mt-4 sm:mt-6\",\"value\":\"professional\",\"children\":[[\"$\",\"div\",null,{\"className\":\"bg-blue-50 border border-blue-200 rounded-lg p-1\",\"children\":[\"$\",\"$L24\",null,{\"id\":\"highlights\",\"title\":\"HIGHLIGHTS\",\"defaultExpanded\":true,\"children\":[\"$\",\"div\",null,{\"className\":\"prose max-w-none\",\"children\":[[\"$\",\"h4\",null,{\"className\":\"text-sm font-medium text-blue-900 mb-2\",\"children\":\"Dosage and Administration Highlights\"}],[\"$\",\"div\",null,{\"dangerouslySetInnerHTML\":{\"__html\":\"\u003cp\u003eThe recommended starting dosage of MOUNJARO is 2.5 mg injected subcutaneously once weekly. After 4 weeks, increase the dosage to 5 mg injected subcutaneously once weekly.\u003c/p\u003e\"}}]]}]}]}],[\"$\",\"div\",null,{\"className\":\"border-2 border-red-500 bg-red-50 rounded-lg p-1\",\"children\":[\"$\",\"$L24\",null,{\"id\":\"boxed-warning\",\"title\":\"BOXED WARNING\",\"defaultExpanded\":true,\"children\":[\"$\",\"div\",null,{\"className\":\"prose max-w-none\",\"dangerouslySetInnerHTML\":{\"__html\":\"\u003cp\u003e\u003cstrong\u003eWARNING: RISK OF THYROID C-CELL TUMORS\u003c/strong\u003e\u003c/p\u003e\u003cp\u003eIn rodents, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors. It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans.\u003c/p\u003e\"}}]}]}],\"$undefined\",[\"$\",\"$L24\",null,{\"id\":\"indications\",\"title\":\"INDICATIONS AND USAGE\",\"defaultExpanded\":true,\"children\":[\"$\",\"div\",null,{\"className\":\"prose max-w-none\",\"dangerouslySetInnerHTML\":{\"__html\":\"\u003cp\u003eMOUNJARO is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.\u003c/p\u003e\"}}]}],[\"$\",\"$L24\",null,{\"id\":\"dosage\",\"title\":\"DOSAGE AND ADMINISTRATION\",\"children\":[\"$\",\"div\",null,{\"className\":\"prose max-w-none\",\"dangerouslySetInnerHTML\":{\"__html\":\"\u003cp\u003eThe recommended starting dosage of MOUNJARO is 2.5 mg injected subcutaneously once weekly. After 4 weeks, increase the dosage to 5 mg injected subcutaneously once weekly.\u003c/p\u003e\"}}]}],\"$undefined\",[\"$\",\"$L24\",null,{\"id\":\"contraindications\",\"title\":\"CONTRAINDICATIONS\",\"children\":[\"$\",\"div\",null,{\"className\":\"prose max-w-none\",\"dangerouslySetInnerHTML\":{\"__html\":\"\u003cp\u003eMOUNJARO is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2.\u003c/p\u003e\"}}]}],[\"$\",\"$L24\",null,{\"id\":\"warnings\",\"title\":\"WARNINGS AND PRECAUTIONS\",\"children\":[\"$\",\"div\",null,{\"className\":\"prose max-w-none\",\"dangerouslySetInnerHTML\":{\"__html\":\"\u003cp\u003e\u003cstrong\u003ePancreatitis:\u003c/strong\u003e Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists.\u003c/p\u003e\"}}]}],[\"$\",\"$L24\",null,{\"id\":\"adverse-reactions\",\"title\":\"ADVERSE REACTIONS\",\"children\":[\"$\",\"div\",null,{\"className\":\"prose max-w-none\",\"dangerouslySetInnerHTML\":{\"__html\":\"\u003cp\u003eThe most common adverse reactions reported in ≥5% of patients treated with MOUNJARO are nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, and abdominal pain.\u003c/p\u003e\"}}]}],[\"$\",\"$L24\",null,{\"id\":\"drug-interactions\",\"title\":\"DRUG INTERACTIONS\",\"children\":[\"$\",\"div\",null,{\"className\":\"prose max-w-none\",\"dangerouslySetInnerHTML\":{\"__html\":\"\u003cp\u003eMOUNJARO delays gastric emptying, and thereby has the potential to impact the absorption of concomitantly administered oral medications.\u003c/p\u003e\"}}]}],\"$undefined\",[\"$\",\"$L24\",null,{\"id\":\"clinical-pharmacology\",\"title\":\"CLINICAL PHARMACOLOGY\",\"children\":[\"$\",\"div\",null,{\"className\":\"prose max-w-none\",\"dangerouslySetInnerHTML\":{\"__html\":\"\u003cp\u003eTirzepatide is a 39-amino-acid modified peptide with a C20 fatty diacid moiety that enables albumin binding and prolongs the half-life.\u003c/p\u003e\"}}]}],\"$undefined\",[\"$\",\"$L24\",null,{\"id\":\"nonclinical-toxicology\",\"title\":\"NONCLINICAL TOXICOLOGY\",\"children\":\"$L25\"}],\"$L26\",\"$L27\",\"$L28\",\"$undefined\",\"$L29\",\"$L2a\",\"$L2b\"]}]\n"])</script><script>self.__next_f.push([1,"1e:[\"$\",\"$L23\",null,{\"ref\":\"$undefined\",\"className\":\"ring-offset-background focus-visible:outline-none focus-visible:ring-2 focus-visible:ring-ring focus-visible:ring-offset-2 space-y-4 sm:space-y-6 mt-4 sm:mt-6\",\"value\":\"patient\",\"children\":[\"$\",\"$L2c\",null,{\"content\":{\"patientFriendlyName\":\"Mounjaro (tirzepatide)\",\"whatItTreats\":\"Used to diet and exercise to improve glycemic control in adults who have type 2 diabetes.\",\"howItWorks\":\"Tirzepatide is a modified peptide that diacid moiety that helps the medication last longer in your body.\",\"commonSideEffects\":[\"Nausea\",\"Diarrhea\",\"Vomiting\",\"Constipation\",\"Abdominal pain\",\"Decreased appetite\"],\"importantSafetyInfo\":\"Pancreatitis: Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists.\",\"whenToCall\":[\"Severe stomach pain that does not go away\",\"Any severe or unusual side effects\",\"Questions about your treatment\"]}}]}]\n"])</script><script>self.__next_f.push([1,"1f:[\"$\",\"$L23\",null,{\"ref\":\"$undefined\",\"className\":\"ring-offset-background focus-visible:outline-none focus-visible:ring-2 focus-visible:ring-ring focus-visible:ring-offset-2 space-y-4 sm:space-y-6 mt-4 sm:mt-6\",\"value\":\"faq\",\"children\":[[\"$\",\"$L2d\",null,{\"faqs\":[{\"question\":\"How should Mounjaro be taken?\",\"answer\":\"The usual starting dose of MOUNJARO is 2.5 mg given as an injection under the skin once a week. After 4 weeks, increase the dosage to 5 mg injected subcutaneously once weekly.\",\"category\":\"dosing\"},{\"question\":\"Who should not take Mounjaro?\",\"answer\":\"MOUNJARO should not be used by people with a personal or family history of certain types of thyroid cancer or in patients with Multiple Endocrine Neoplasia syndrome type 2.\",\"category\":\"safety\"},{\"question\":\"What are the most common side effects of Mounjaro?\",\"answer\":\"The most common adverse reactions experienced by 5% or more of people taking MOUNJARO are nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, and abdominal pain.\",\"category\":\"side-effects\"},{\"question\":\"How should Mounjaro be stored?\",\"answer\":\"Follow storage instructions on the package. Keep out of reach of children.\",\"category\":\"storage\"},{\"question\":\"What conditions does Mounjaro treat?\",\"answer\":\"Used to diet and exercise to improve glycemic control in adults who have type 2 diabetes.\",\"category\":\"usage\"}],\"drugName\":\"Mounjaro\"}],[\"$\",\"$L2e\",null,{\"content\":{\"similarDrugs\":[],\"relatedConditions\":[\"Diabetes\"],\"alternativeTreatments\":[\"Diet and exercise\",\"Metformin\",\"Insulin therapy\",\"SGLT-2 inhibitors\"]}}]]}]\n"])</script><script>self.__next_f.push([1,"20:[\"$\",\"div\",null,{\"className\":\"lg:col-span-1\",\"children\":[\"$\",\"div\",null,{\"ref\":\"$undefined\",\"className\":\"rounded-lg border bg-card text-card-foreground shadow-sm p-4 sm:p-6 sticky top-4 sm:top-8\",\"children\":[[\"$\",\"h3\",null,{\"className\":\"font-semibold mb-4\",\"children\":\"Drug Information\"}],[\"$\",\"dl\",null,{\"className\":\"space-y-3 text-sm\",\"children\":[[\"$\",\"dt\",null,{\"className\":\"text-gray-600\",\"children\":\"Drug Name\"}],[\"$\",\"dd\",null,{\"className\":\"font-medium\",\"children\":\"Mounjaro\"}],[[\"$\",\"dt\",null,{\"className\":\"text-gray-600 mt-3\",\"children\":\"Generic Name\"}],[\"$\",\"dd\",null,{\"className\":\"font-medium\",\"children\":\"tirzepatide\"}]],[\"$\",\"dt\",null,{\"className\":\"text-gray-600 mt-3\",\"children\":\"Set ID\"}],[\"$\",\"dd\",null,{\"className\":\"font-medium font-mono text-xs\",\"children\":\"d2d7da5d-ad07-4228-955f-cf7e355c8cc0\"}],[[\"$\",\"dt\",null,{\"className\":\"text-gray-600 mt-3\",\"children\":\"Labeler\"}],[\"$\",\"dd\",null,{\"className\":\"font-medium\",\"children\":\"Eli Lilly and Company\"}]],\"$undefined\",\"$undefined\",[[\"$\",\"dt\",null,{\"className\":\"text-gray-600 mt-3\",\"children\":\"Therapeutic Class\"}],[\"$\",\"dd\",null,{\"className\":\"font-medium\",\"children\":\"GLP-1/GIP Receptor Agonist\"}]],[[\"$\",\"dt\",null,{\"className\":\"text-gray-600 mt-3\",\"children\":\"Active Ingredient\"}],[\"$\",\"dd\",null,{\"className\":\"font-medium\",\"children\":\"tirzepatide\"}]],[[\"$\",\"dt\",null,{\"className\":\"text-gray-600 mt-3\",\"children\":\"Manufacturer\"}],[\"$\",\"dd\",null,{\"className\":\"font-medium\",\"children\":\"Eli Lilly and Company\"}]],\"$undefined\",[\"$\",\"dt\",null,{\"className\":\"text-gray-600 mt-3\",\"children\":\"Slug\"}],[\"$\",\"dd\",null,{\"className\":\"font-medium text-xs text-gray-500\",\"children\":\"mounjaro-d2d7da5\"}]]}],false]}]}]\n"])</script><script>self.__next_f.push([1,"25:[\"$\",\"div\",null,{\"className\":\"prose max-w-none\",\"dangerouslySetInnerHTML\":{\"__html\":\"\u003cp\u003eIn a 2-year carcinogenicity study in rats, tirzepatide caused a dose-related and treatment-duration-dependent increase in the incidence of thyroid C-cell adenomas and carcinomas.\u003c/p\u003e\"}}]\n26:[\"$\",\"$L24\",null,{\"id\":\"clinical-studies\",\"title\":\"CLINICAL STUDIES\",\"children\":[\"$\",\"div\",null,{\"className\":\"prose max-w-none\",\"dangerouslySetInnerHTML\":{\"__html\":\"\u003cp\u003eThe efficacy of MOUNJARO was evaluated in five multicenter, randomized, controlled trials in adult patients with type 2 diabetes.\u003c/p\u003e\"}}]}]\n27:[\"$\",\"$L24\",null,{\"id\":\"description\",\"title\":\"DESCRIPTION\",\"children\":[\"$\",\"div\",null,{\"className\":\"prose max-w-none\",\"dangerouslySetInnerHTML\":{\"__html\":\"\u003cp\u003eMOUNJARO contains tirzepatide, a GIP receptor and GLP-1 receptor agonist. It is a 39-amino-acid modified peptide.\u003c/p\u003e\"}}]}]\n28:[\"$\",\"$L24\",null,{\"id\":\"how-supplied\",\"title\":\"HOW SUPPLIED/STORAGE AND HANDLING\",\"children\":[\"$\",\"div\",null,{\"className\":\"prose max-w-none\",\"dangerouslySetInnerHTML\":{\"__html\":\"\u003cp\u003eMOUNJARO is supplied as a single-dose pen containing a 0.5 mL solution in the following dosage strengths: 2.5 mg/0.5 mL, 5 mg/0.5 mL, 7.5 mg/0.5 mL, 10 mg/0.5 mL, 12.5 mg/0.5 mL, and 15 mg/0.5 mL.\u003c/p\u003e\"}}]}]\n29:[\"$\",\"$L24\",null,{\"id\":\"patient-counseling\",\"title\":\"PATIENT COUNSELING INFORMATION\",\"children\":[\"$\",\"div\",null,{\"className\":\"prose max-w-none\",\"dangerouslySetInnerHTML\":{\"__html\":\"\u003cp\u003eAdvise the patient to read the FDA-approved patient labeling (Medication Guide and Instructions for Use).\u003c/p\u003e\"}}]}]\n2a:[\"$\",\"$L24\",null,{\"id\":\"overdosage\",\"title\":\"OVERDOSAGE\",\"children\":[\"$\",\"div\",null,{\"className\":\"prose max-w-none\",\"dangerouslySetInnerHTML\":{\"__html\":\"\u003cp\u003eIn the event of overdosage, contact Poison Control for latest recommendations. Based on the pharmacological actions of tirzepatide, an overdose may result in gastrointestinal adverse reactions and hypoglycemia.\u003c/p\u003e\"}}]}]\n2b:[\"$\",\"$L24\",null,{\"id\":\"principal-display-panel\",\"title\":\"PRINCIPAL DISPLAY PANEL\",\"children\":[\"$"])</script><script>self.__next_f.push([1,"\",\"div\",null,{\"className\":\"prose max-w-none\",\"dangerouslySetInnerHTML\":{\"__html\":\"\u003cp\u003eNDC 0002-1434-80\u003cbr/\u003eMOUNJARO™\u003cbr/\u003e(tirzepatide) injection\u003cbr/\u003e2.5 mg/0.5 mL\u003cbr/\u003eFor subcutaneous use only\u003cbr/\u003eSingle-Dose Pen\u003cbr/\u003eRx only\u003c/p\u003e\"}}]}]\n"])</script></body></html>